Average Co-Inventor Count = 4.48
ph-index = 16
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Novo Nordisk A/s (24 from 1,778 patents)
2. Novo Nordisk Healthcare Ag (10 from 88 patents)
3. Other (6 from 832,912 patents)
4. Sanquin Blood Supply Foundation (3 from 3 patents)
5. Unilever Plc (2 from 4 patents)
6. Novozymes A/s (1 from 1,371 patents)
7. Novo Nordisk Helathcare A/g (1 from 1 patent)
8. Stichting Sanquin Bloedvoorziening (27 patents)
9. Unilever, N.v. (3 patents)
10. Leif Norskov-Lauritsen (0 patent)
11. Sven Branner (0 patent)
12. Sven Hastrup (0 patent)
13. Merete Simonsen (0 patent)
14. Ole H. Olsen (0 patent)
15. Dorrit Aaslyng (0 patent)
43 patents:
1. 10906960 - Factor VIII variants having a decreased cellular uptake
2. 10047142 - Factor VIII variants having a decreased cellular uptake
3. 9574011 - Antibodies against tissue factor pathway inhibitor
4. 9493543 - Factor VIII fusion protein
5. 9370583 - Coagulation factor VII polypeptides
6. 9371370 - Coagulation factor VII polypeptides
7. 9321827 - Factor VIII variants having a decreased cellular uptake
8. 9125890 - Compounds suitable for treatment of haemophilia
9. 8652471 - Methods of treating coagulopathies using antibodies against tissue factor pathway inhibitor
10. 8513192 - Stable growth hormone compounds resistant to proteolytic degradation
11. 8361469 - Antibodies against tissue factor pathway inhibitor
12. 7695935 - Nucleic acids encoding human coagulation FVII polypeptides
13. 7419803 - Nucleic acids encoding human coagulation Factor VII polypeptides
14. 7416861 - Human coagulation factor VII polypeptides
15. 7416860 - Nucleic acids encoding human coagulation factor VII variants